Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT06236438
Title Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)
Acronym LIVIGNO-4
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors AbbVie
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Bond & Steele Clinic, P.A. /ID# 262611 RECRUITING Winter Haven Florida 33881-4111 United States Details
Cancer & Hematology Centers of Western Michigan - East /ID# 261826 RECRUITING Grand Rapids Michigan 49546-7062 United States Details
Vista Oncology - East Olympia /ID# 262303 RECRUITING Olympia Washington 98506-5028 United States Details
Rambam Health Care Campus /ID# 262431 RECRUITING Haifa H_efa 3109601 Israel Details
Shaare Zedek Medical Center /ID# 262432 RECRUITING Jerusalem Yerushalayim 91031 Israel Details
Saitama Cancer Center /ID# 262703 RECRUITING Kitaadachi-gun Saitama 362-0806 Japan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field